News

September 29, 2015 3:15 pm
Janssen-Cilag International NV announced on September 25, 2015 that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has accepted its request for an accelerated assessment of the daratumumab...
September 29, 2015 3:00 pm
The results of the first clinical trial to investigate carfilzomib (Kyprolis®), pomalidomide (Pomalyst®), and dexamethasone (CPD) in multiple myeloma were published last week in the journal BLOOD . IMF Chairman Dr. Brian Durie, co-author of the...
September 22, 2015 3:45 pm
  The US Food and Drug Administration (FDA) has agreed for priority review of Amgen’s supplemental new drug application (sNDA) for expanded labeling of Kyprolis (carfilzomib) in relapsed multiple myeloma.
September 22, 2015 3:45 pm
Takeda Pharmaceutical Company Limited on September 22, 2015 announced that it will highlight the ixazomib clinical development program during multiple poster sessions at the upcoming 15th International Myeloma Workshop (IMW 2015) to be held in Rome...

Pages